表紙
市場調查報告書
商品編碼
982421

全球C型肝炎治療藥市場(2021年-2025年)

Global Hepatitis C Drugs Market 2021-2025

出版日期: | 出版商: TechNavio (Infiniti Research Ltd.) | 英文 120 Pages | 訂單完成後即時交付

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球C型肝炎治療藥的市場規模在2021年∼2025年間,預測將成長到2億5,289萬美元,這個期間中的年複合成長率預測將為1%。市場成長的主要因素有直接作用型抗病毒藥物的需求增加和支援患者舉措的增加。

本報告提供C型肝炎治療藥市場調查,提供市場概要,市場成長要素及阻礙因素分析,各類型·各地區的市場規模的變化與預測,供應商分析,市場機會等全面性資訊。

目錄

摘要整理

市場形勢

市場規模

  • 市場定義
  • 市場區隔分析
  • 市場規模2020
  • 市場預測:從2020年∼2025年的預測

波特的五力分析

各產品的市場區隔

  • 市場區隔
  • 各產品比較
  • 聯合治療-市場規模與預測(2020年∼2025年)
  • 單劑療法-市場規模與預測(2020年∼2025年)
  • 各產品的市場機會

客戶形勢

各地區形勢

  • 各地區市場區隔
  • 各地區比較
  • 北美-市場規模與預測(2020年∼2025年)
  • 歐洲-市場規模與預測(2020年∼2025年)
  • 亞洲-市場規模與預測(2020年∼2025年)
  • 其他地區-市場規模與預測(2020年∼2025年)
  • 主要的主要國家
  • 地區的市場機會
  • 市場推動因素
  • 市場課題
  • 市場趨勢

業者情勢

  • 競爭模式
  • 業者情勢
  • 創造性破壞狀況
  • 產業的風險

供應商分析

  • 交易廠商
  • 供應商的市場定位
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Bristol-Myers Squibb Co.
  • Cipla Inc.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Vertex Pharmaceuticals Inc.

附錄

目錄
Product Code: IRTNTR46518

Technavio has been monitoring the hepatitis C drugs market and it is poised to grow by $ 252.89 mn during 2021-2025 progressing at a CAGR of 1% during the forecast period. Our report on hepatitis C drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing demand for direct-acting antivirals and rising number of patient support initiatives. In addition, increasing demand for direct-acting antivirals is anticipated to boost the growth of the market as well.

The hepatitis C drugs market analysis includes product segments and geographical landscapes.

Technavio's hepatitis C drugs market is segmented as below:

By Product

  • Combination therapy
  • Monotherapy

By Geographical Landscapes

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the high prevalence of hepatitis C as one of the prime reasons driving the hepatitis C drugs market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on hepatitis C drugs market covers the following areas:

  • Hepatitis C drugs market sizing
  • Hepatitis C drugs market forecast
  • Hepatitis C drugs market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading hepatitis c drugs market vendors that include AbbVie Inc., Astellas Pharma Inc., Bristol-Myers Squibb Co., Cipla Inc., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. Inc., and Vertex Pharmaceuticals Inc. Also, the hepatitis c drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Market Characteristics
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2020
  • Market outlook: Forecast for 2020 - 2025

Five Forces Analysis

  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Product

  • Market segments
  • Comparison by Product
  • Combination therapy - Market size and forecast 2020-2025
  • Monotherapy - Market size and forecast 2020-2025
  • Market opportunity by Product

Customer landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2020-2025
  • Europe - Market size and forecast 2020-2025
  • Asia - Market size and forecast 2020-2025
  • ROW - Market size and forecast 2020-2025
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape

  • Competitive scenario
  • Vendor landscape
  • Landscape disruption
  • Industry risks

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Bristol-Myers Squibb Co.
  • Cipla Inc.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Vertex Pharmaceuticals Inc.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2020 - 2025 ($ million)
  • 13: Global market: Year-over-year growth 2020 - 2025 (%)
  • 14: Five forces analysis 2020 & 2025
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2020
  • 21: Product - Market share 2020-2025 (%)
  • 22: Comparison by Product
  • 23: Combination therapy - Market size and forecast 2020-2025 ($ million)
  • 24: Combination therapy - Year-over-year growth 2020-2025 (%)
  • 25: Monotherapy - Market size and forecast 2020-2025 ($ million)
  • 26: Monotherapy - Year-over-year growth 2020-2025 (%)
  • 27: Market opportunity by Product
  • 28: Customer landscape
  • 29: Market share by geography 2020-2025 (%)
  • 30: Geographic comparison
  • 31: North America - Market size and forecast 2020-2025 ($ million)
  • 32: North America - Year-over-year growth 2020-2025 (%)
  • 33: Europe - Market size and forecast 2020-2025 ($ million)
  • 34: Europe - Year-over-year growth 2020-2025 (%)
  • 35: Asia - Market size and forecast 2020-2025 ($ million)
  • 36: Asia - Year-over-year growth 2020-2025 (%)
  • 37: ROW - Market size and forecast 2020-2025 ($ million)
  • 38: ROW - Year-over-year growth 2020-2025 (%)
  • 39: Key leading countries
  • 40: Market opportunity by geography ($ million)
  • 41: Impact of drivers and challenges
  • 42: Vendor landscape
  • 43: Landscape disruption
  • 44: Industry risks
  • 45: Vendors covered
  • 46: Market positioning of vendors
  • 47: AbbVie Inc. - Overview
  • 48: AbbVie Inc. - Business segments
  • 49: AbbVie Inc. - Key offerings
  • 50: AbbVie Inc. - Key customers
  • 51: AbbVie Inc. - Segment focus
  • 52: Astellas Pharma Inc. - Overview
  • 53: Astellas Pharma Inc. - Business segments
  • 54: Astellas Pharma Inc. - Key offerings
  • 55: Astellas Pharma Inc. - Key customers
  • 56: Astellas Pharma Inc. - Segment focus
  • 57: Bristol-Myers Squibb Co. - Overview
  • 58: Bristol-Myers Squibb Co. - Business segments
  • 59: Bristol-Myers Squibb Co. - Key offerings
  • 60: Bristol-Myers Squibb Co. - Key customers
  • 61: Bristol-Myers Squibb Co. - Segment focus
  • 62: Cipla Inc. - Overview
  • 63: Cipla Inc. - Business segments
  • 64: Cipla Inc. - Key offerings
  • 65: Cipla Inc. - Key customers
  • 66: Cipla Inc. - Segment focus
  • 67: F. Hoffmann-La Roche Ltd. - Overview
  • 68: F. Hoffmann-La Roche Ltd. - Business segments
  • 69: F. Hoffmann-La Roche Ltd. - Key offerings
  • 70: F. Hoffmann-La Roche Ltd. - Key customers
  • 71: F. Hoffmann-La Roche Ltd. - Segment focus
  • 72: Gilead Sciences Inc. - Overview
  • 73: Gilead Sciences Inc. - Business segments
  • 74: Gilead Sciences Inc. - Key offerings
  • 75: Gilead Sciences Inc. - Key customers
  • 76: Gilead Sciences Inc. - Segment focus
  • 77: GlaxoSmithKline Plc - Overview
  • 78: GlaxoSmithKline Plc - Business segments
  • 79: GlaxoSmithKline Plc - Key offerings
  • 80: GlaxoSmithKline Plc - Key customers
  • 81: GlaxoSmithKline Plc - Segment focus
  • 82: Johnson & Johnson - Overview
  • 83: Johnson & Johnson - Business segments
  • 84: Johnson & Johnson - Key offerings
  • 85: Johnson & Johnson - Key customers
  • 86: Johnson & Johnson - Segment focus
  • 87: Merck & Co. Inc. - Overview
  • 88: Merck & Co. Inc. - Business segments
  • 89: Merck & Co. Inc. - Key offerings
  • 90: Merck & Co. Inc. - Key customers
  • 91: Merck & Co. Inc. - Segment focus
  • 92: Vertex Pharmaceuticals Inc. - Overview
  • 93: Vertex Pharmaceuticals Inc. - Business segments
  • 94: Vertex Pharmaceuticals Inc. - Key offerings
  • 95: Vertex Pharmaceuticals Inc. - Key customers
  • 96: Vertex Pharmaceuticals Inc. - Segment focus
  • 97: Currency conversion rates for US$
  • 98: Research Methodology
  • 99: Validation techniques employed for market sizing
  • 100: Information sources
  • 101: List of abbreviations